372 related articles for article (PubMed ID: 25365104)
1. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
2. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
4. Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis.
Yu C; Li M; Duan X; Fang Y; Li Q; Wu R; Liu S; Wang Y; Wu Z; Shi X; Jiang Z; Wang Y; Hsieh ED; Jin S; Jiang N; Wang Q; Zhao Y; Tian X; Zeng X;
Clin Exp Rheumatol; 2018; 36(5):836-840. PubMed ID: 29600939
[TBL] [Abstract][Full Text] [Related]
5. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
6. Treating rheumatoid arthritis to target: an Italian rheumatologists' survey on the acceptance of the treat-to-target recommendations.
Caporali R; Conti F; Covelli M; Govoni M; Salaffi F; Ventriglia G; Montecucco C
Clin Exp Rheumatol; 2014; 32(4):471-6. PubMed ID: 24960620
[TBL] [Abstract][Full Text] [Related]
7. Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
Tan BE; Lim AL; Kan SL; Lim CH; Ng YF; Tng SLC; Hassin NS; Chandran L; Hamid NA; Lee YYL
Rheumatol Int; 2017 Jun; 37(6):905-913. PubMed ID: 28389855
[TBL] [Abstract][Full Text] [Related]
8. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
10. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
[TBL] [Abstract][Full Text] [Related]
11. Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation.
Markusse IM; Dirven L; Han KH; Ronday HK; de Sonnaville PB; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):446-53. PubMed ID: 26239288
[TBL] [Abstract][Full Text] [Related]
12. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
[TBL] [Abstract][Full Text] [Related]
13. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg BJ; Boesen M; Hetland ML; Christensen R; Møller J; Krogh NS; Stengaard-Pedersen K; Østergaard M
Trials; 2015 Apr; 16():178. PubMed ID: 25896862
[TBL] [Abstract][Full Text] [Related]
14. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
16. In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols.
Balduzzi S; Scirè CA; Sakellariou G; Benaglio F; Bugatti S; Montecucco C; Caporali R
Clin Exp Rheumatol; 2017; 35(3):401-405. PubMed ID: 27974097
[TBL] [Abstract][Full Text] [Related]
17. Modern treatment strategies in rheumatoid arthritis.
Hetland ML
Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
[TBL] [Abstract][Full Text] [Related]
18. Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy.
Wabe N; Wiese MD
J Eval Clin Pract; 2017 Jun; 23(3):486-493. PubMed ID: 27650675
[TBL] [Abstract][Full Text] [Related]
19. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control.
Littlejohn G; Roberts L; Arnold M; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Scott J; Zochling J; Tymms KE
Int J Rheum Dis; 2013 Oct; 16(5):532-8. PubMed ID: 24164840
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
